Esperion Therapeutics (ESPR) Leases: 2019-2025
Historic Leases for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to $3.3 million.
- Esperion Therapeutics' Leases fell 46.56% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 46.56%. This contributed to the annual value of $5.5 million for FY2024, which is 17.93% up from last year.
- As of Q3 2025, Esperion Therapeutics' Leases stood at $3.3 million, which was down 21.45% from $4.2 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Leases registered a high of $7.1 million during Q1 2024, and its lowest value of $730,000 during Q3 2022.
- Over the past 3 years, Esperion Therapeutics' median Leases value was $4.7 million (recorded in 2023), while the average stood at $4.5 million.
- Its Leases has fluctuated over the past 5 years, first crashed by 80.35% in 2022, then spiked by 563.26% in 2024.
- Esperion Therapeutics' Leases (Quarterly) stood at $1.9 million in 2021, then tumbled by 45.42% to $1.0 million in 2022, then skyrocketed by 351.25% to $4.7 million in 2023, then grew by 17.93% to $5.5 million in 2024, then tumbled by 46.56% to $3.3 million in 2025.
- Its last three reported values are $3.3 million in Q3 2025, $4.2 million for Q2 2025, and $5.0 million during Q1 2025.